For the treatment of their underlying plasma cell dyscrasia, 72% of patients received a proteasome inhibitor, 56% an alkylating agent, 30% an immunomodulatory drug and 9% an anti-CD38 monoclonal antibody. The gene discussed is CD38; the disease is plasma cell neoplasm.